Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott H Okuno

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Cancer Medicine|August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial resultsSteven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Sarcoma|August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Journal of Surgical Oncology|February 13, 2023
Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG OncologyMark L Kayton, Aaron R Weiss, Wei Xue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the BreastAmy C Degnim, Brittany L Siontis, Safia K Ahmed, et al.
Oral Oncology|January 29, 2014
Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinomaJessica L Geiger, Ahmed F Lazim, Francis J Walsh, et al.
The Oncologist|July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 StudyRichard F Riedel, Karla V Ballman, Yao Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Quality of life and symptom burden among long-term lung cancer survivorsPing Yang, Andrea L Cheville, Jason A Wampfler, et al.
Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to PembrolizumabEmily Z Keung, Melissa Burgess, Ruth Salazar, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Cancer Medicine|August 11, 2022
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial resultsSteven Attia, Vanessa Bolejack, Kristen N Ganjoo, et al.
Sarcoma|August 21, 2019
Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)Brigitte C Widemann, Yao Lu, Denise Reinke, et al.
Journal of Surgical Oncology|February 13, 2023
Neoadjuvant pazopanib in nonrhabdomyosarcoma soft tissue sarcomas (ARST1321): A report of major wound complications from the Children's Oncology Group and NRG OncologyMark L Kayton, Aaron R Weiss, Wei Xue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2023
Trimodality Therapy Improves Disease Control in Radiation-Associated Angiosarcoma of the BreastAmy C Degnim, Brittany L Siontis, Safia K Ahmed, et al.
Oral Oncology|January 29, 2014
Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinomaJessica L Geiger, Ahmed F Lazim, Francis J Walsh, et al.
The Oncologist|July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 StudyRichard F Riedel, Karla V Ballman, Yao Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2011
Quality of life and symptom burden among long-term lung cancer survivorsPing Yang, Andrea L Cheville, Jason A Wampfler, et al.
Sarcoma|May 14, 2020
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the LungKristin Baird, John Glod, Seth M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2021
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1Sant P Chawla, Brian A Van Tine, Seth M Pollack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2020
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to PembrolizumabEmily Z Keung, Melissa Burgess, Ruth Salazar, et al.
Pageof 9